ClinicalTrials.gg
RecruitingNCT06909539HoPe FITUpdated Oct 20, 2026

HOme PElvic Floor Improvement Trainer Trial

An interventional study of Home Pelvic Floor Trainer in Pelvic Pain, Pelvic Floor Dysfunction and Voiding Dysfunction, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Pelvic Pain with a site in United States — 37 open to participants now, 40 under way, 1 of them phase 3. Pelvic Pain · United States.

Planned enrollment
18th of 124
150 · median 50
Started
2026
with 14 others
No phase
72 of 152
23 open now
Primary completion
2028-11
later than 32 of 39 live
Registered
136th of 152
by date

Among the 152 studies in Pelvic Pain with a site in United States, this one is the 18th largest by planned enrollment of the 124 interventional ones that give a count, is one of 15 that started in 2026, is one of 72 with no phase, reaches primary completion later than 32 of the 39 other live ones, and was the 136th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

37 of the 152 studies in Pelvic Pain with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pelvic Pain with a site in United States, or all of them as a file.
02

Study summary

This study will gauge the efficacy of a home biofeedback treatment device for pelvic floor dysfunction/voiding dysfunction and pelvic pain. Investigators will test the utility of this device as a treatment alternative and/or temporary treatment for a patient's symptoms prior to or perhaps in lieu of their physical therapy appointment.

Read the detailed description

This study aims to determine if a special device can help children with pelvic floor problems. The pelvic floor issues under investigation include difficulty controlling urination and ongoing pain in the lower belly. The study will explore whether the device helps children gain better control over urination.

It will also investigate if the device contributes to the reduction of pelvic pain experienced by children. Furthermore, the study will analyze if the device leads to improvement in how the body functions during urination. The consistency with which children use the device and adhere to instructions will be monitored. Finally, the study includes an assessment of whether children find the device acceptable for use.

03

Conditions studied

  • Pelvic Pain
  • Pelvic Floor Dysfunction
  • Voiding Dysfunction

Browse trials for

Keywords

  • voiding dysfunction
  • pelvic floor dysfunction
  • pelvic pain
  • perineometer
  • gamification
  • pelvic floor physical therapy
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-speaking only.
  • Dysfunctional voiding symptoms without chronic pelvic pain.
  • Chronic pelvic pain with or without dysfunctional voiding symptoms (daytime enuresis, nocturnal enuresis, frequency, urgency, dysuria)
  • 8 years - 18 years, no one under 8 and no one over 18.
  • Patient received PVR and uroflow at initial urology consult visit.
  • Patient or parent has an Apple product (ie: iPhone, or tablet). The application is only available via Apple products.

Exclusion criteria

Exclusion Criteria:

  • Non-English speaking.
  • Has seen a physical therapist for traditional physical therapy of the pelvic floor due to urinary symptoms or chronic pelvic pain within the last 12 months.

Note: This would include patients who begin physical therapy for their pelvic floor outside of the study while enrolled in the study.

- All patients with the following conditions: severe developmental delay such as CP or wheelchair bound, cannot eat by mouth, mechanical ventilation dependence, etc.

  • Nonverbal or unable to effectively communicate needs and preferences.
  • Within the voiding dysfunction group, a diagnosis of a congenital GU anomaly (bladder exstrophy, cloacal anomaly, spina bifida, etc.)
  • No initial medication usage will be excluded; however, if the patient begins a new medication or treatment regimen during the study, the patient will be excluded.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Voiding Dysfunction

    Patients with voiding dysfunction only and no pelvic pain symptoms will use the home pelvic floor trainer daily for 2 months.

    Device: Home Pelvic Floor Trainer

  • Experimental
    Pelvic pain

    Patients with pelvic pain with or without voiding dysfunction symptoms will use the home pelvic floor trainer daily for 2 months.

    Device: Home Pelvic Floor Trainer

Interventions

  • DeviceHome Pelvic Floor Trainer

    The intervention utilizes a perineometer device with biofeedback features. This device employs external electrodes to measure pelvic floor muscle strength. It then provides real-time feedback through a smartphone application during exercise sessions. The application uses gamification to engage users and track progress. Patients can choose between two games: a bird game or a space-themed game. In the bird game, patients activate their pelvic floor muscles to make the bird fly upward. In the space game, pelvic floor contractions fire a laser or activate a shield. A visual bar displays the strength of pelvic floor contractions. Games are designed to be played for 5 minutes daily, 7 days a week, with increasing difficulty as the user progresses through levels.

06

What researchers measure

Primary outcomes

  1. Dysfunctional Voiding Symptom Scale (30 point scale)

    This survey will be given to all participants and is the primary outcome of the DV group. This will be attained before the start of treatment, at 4-week mark, and at 8-week visit. The DVSS is a 30 point scale with higher scores representing more severe voiding dysfunction symptoms. Males with score greater than 9 points are considered to have voiding dysfunction, and females with score greater than 6 are considered to have voiding dysfunction.

    Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the DVSS survey

  2. McGill Pain Scale (Short Form - points scale)

    This survey will be given to all participants and is the primary outcome of the Pelvic Pain group. This will be attained before the start of treatment, at 4-week mark, and 8-week visit. Total of 22 items with 0-10 numerical response options, 0 being no pain and the higher score representing more pain)

    Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill Pain Scale Short Form survey

Secondary outcomes

  1. Post-Void Residual Volume (mL)

    PVR volume \> 10% normal will be considered elevated PVR. This will be attained from all participants at an initial baseline urology visit as part of standard of care, and the 8-week in-person visit.

    Time frame: 0 weeks baseline, 8 weeks in-person visits investigators will attain PVR

  2. Uroflowmetry

    Uroflowmetry parameters will be assessed at the initial and 8-week visits. These parameters include: A normal, bell-shaped curve. A tower flow curve, suggesting detrusor overactivity. A staccato flow curve, suggesting external sphincter activity. An intermittent or interrupted flow curve, suggesting underactive detrusor or dysfunctional voiding. A plateau shape curve, suggesting bladder outlet obstruction

    Time frame: Investigators will attain uroflowmetry at the same time as the PVR measurement, at initial baseline (0 weeks) and last (8 weeks) in-person visits.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Skardoon GR, Khera AJ, Emmanuel AV, Burgell RE. Review article: dyssynergic defaecation and biofeedback therapy in the pathophysiology and management of functional constipation. Aliment Pharmacol Ther. 2017 Aug;46(4):410-423. doi: 10.1111/apt.14174. Epub 2017 Jun 29. PubMed 28660663 ↗
  • Vasconcelos M, Lima E, Caiafa L, Noronha A, Cangussu R, Gomes S, Freire R, Filgueiras MT, Araujo J, Magnus G, Cunha C, Colozimo E. Voiding dysfunction in children. Pelvic-floor exercises or biofeedback therapy: a randomized study. Pediatr Nephrol. 2006 Dec;21(12):1858-64. doi: 10.1007/s00467-006-0277-1. Epub 2006 Sep 12. PubMed 16967285 ↗
  • Wagner B, Steiner M, Huber DFX, Crevenna R. The effect of biofeedback interventions on pain, overall symptoms, quality of life and physiological parameters in patients with pelvic pain : A systematic review. Wien Klin Wochenschr. 2022 Jan;134(Suppl 1):11-48. doi: 10.1007/s00508-021-01827-w. Epub 2021 Mar 22. PubMed 33751183 ↗
  • Taylor AS, Cabo JJ, Lauderdale C, Maskan N, Thomas JC, Tanaka ST, Pope JC, Adams MC, Brock JW, Shannon CN, Clayton DB. Pelvic floor biofeedback therapy in children: Assessment of symptom scores in responders and non-responders. Neurourol Urodyn. 2019 Jan;38(1):254-260. doi: 10.1002/nau.23842. Epub 2018 Oct 23. PubMed 30350888 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.

Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 24 months is above that.

Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jun 2025 → Nov 2026, primary completion Jan 2027 → Nov 2028 and completion Jan 2027 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartEst.
Nov 1, 2026was Jun 2025
Primary completionEst.
Nov 1, 2028was Jan 2027
CompletionEst.
Nov 1, 2028was Jan 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
University of Colorado Anschutz is now Recruiting
Oct 20, 2026
Start date
Jun 1, 2025→Nov 1, 2026
Oct 20, 2026
Primary completion
Jan 1, 2027→Nov 1, 2028
Oct 20, 2026
Study completion
Jan 1, 2027→Nov 1, 2028
Oct 20, 2026
Eligibility
1 inclusion criterion edited, 3 added, 1 removed; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedEnglish-speaking only.
  • RemovedChronic pelvic pain with or without dysfunctional voiding symptoms.
  • EditedDaytimeChronic pelvic pain with or without dysfunctional voiding symptoms (daytime enuresis, nocturnal enuresis, frequency, urgency, dysuria)
  • AddedPatient received PVR and uroflow at initial urology consult visit.
  • AddedPatient or parent has an Apple product (ie: iPhone, or tablet). The application is only available via Apple products.
Exclusion criteria
  • AddedNon-English speaking.
  • Edited- All patients with the following conditions: severe developmental delay such as CP or wheelchair bound, cannot eat by mouth, mechanical ventilation dependence, etc.
Oct 20, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedDysfunctional Voiding symptom scaleSymptom Scale (30 point scale)Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the DVSS survey
  • EditedMcGill Pain Scale (Short Form - points scale)Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill pain Scale Short Form survey → 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill Pain Scale Short Form survey
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    University of Colorado Anschutz is now Recruiting
    Start date Jun 1, 2025→Nov 1, 2026
    Primary completion Jan 1, 2027→Nov 1, 2028
    Study completion Jan 1, 2027→Nov 1, 2028
    Eligibility 1 inclusion criterion edited, 3 added, 1 removed; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedEnglish-speaking only.
    • RemovedChronic pelvic pain with or without dysfunctional voiding symptoms.
    • EditedDaytimeChronic pelvic pain with or without dysfunctional voiding symptoms (daytime enuresis, nocturnal enuresis, frequency, urgency, dysuria)
    • AddedPatient received PVR and uroflow at initial urology consult visit.
    • AddedPatient or parent has an Apple product (ie: iPhone, or tablet). The application is only available via Apple products.
    Exclusion criteria
    • AddedNon-English speaking.
    • Edited- All patients with the following conditions: severe developmental delay such as CP or wheelchair bound, cannot eat by mouth, mechanical ventilation dependence, etc.
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedDysfunctional Voiding symptom scaleSymptom Scale (30 point scale)Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the DVSS survey
    • EditedMcGill Pain Scale (Short Form - points scale)Time frame: 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill pain Scale Short Form survey → 0 weeks baseline, 4 weeks, and 8 weeks patients will take the McGill Pain Scale Short Form survey
    + 4 other changes: index terms, identifiers, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06909539
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Kelly Harris, MD
Contact
kelly.harris2@childrenscolorado.org
(720)777-3926
Kelly Harris, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion